Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss. Improving distant control of lung cancer is the most exciting potential benefit of combining ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

The vaccine is being developed in partnership with Cleveland Clinic and the phase one trial is fully funded by a grant from ...

This special edition of Love Your Maunga will take place at the award-winning Whānau Ātea at the base of Te Pane o Mataoho / ...

When the mud settled, national champion Carl Ruiterman (S22) emerged victorious, completing all 12 laps and once again proving why he wears the NZ1 plate. He was followed closely by Ash Kelly (192) ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma.

Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

Merck ( MRK) is a global biopharmaceutical giant with a diversified portfolio that spans across oncology, vaccines, ...